Leo challenges Novartis with tablet agreement
Leo Pharma has signed a global licensing agreement for a new candidate. It will be the company's first tablet therapy against atopic dermatitis and a possible rival to a drug from Novatis.
With a new licensing agreement with South Korean JW Pharmaceuticals, Leo Pharma has got a hold on a candidate drug in the very early stages.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Leo Pharma boss moves to executive position in Sweden
For abonnenter
